SlideShare una empresa de Scribd logo
1 de 50
Descargar para leer sin conexión
Drugs in pregnancy
 SAMEERSALEH SAWAED
 2016
Drug Epidemiology
 More than 50% of pregnant women take prescribed or non-
prescribed (OTC) drugs or use social drugs (such as tobacco
and alcohol) or illicit drugs at some time during pregnancy.
 In general, drugs should NOT be used during pregnancy
unless absolutely necessary because many can harm the
fetus.
 About 2-3% of all birth defects result from drugs that are
taken to treat a disorder or symptom.
Drug Disposition In The Maternal-fetal
Unit
Maternal Pharmacokinetics
 Changes in body fluid volume
 Changes in CVS parameters
 Changes in pulmonary function
 Alterations in gastric activity
 Changes in serum binding protein concentrations and
occupancy
 Alterations in kidney function
Fetal Pharmacokinetics
 Plasma binding proteins differ from maternal.
 Drugs transferred across placenta undergo 1st pass
through the fetal liver.
 Liver expresses metabolizing enzymes, but capacity less
than mother.
 Fetal kidney immature.
Placental Pharmacokinetics
 Blood flow through the placenta (maternal side) increases during
gestation
 Transfer of flow-limited drugs affected by placental flow
 Compounds that alter blood flow alter maternal drug disposition and
placental transfer
 Placental metabolism (dealkylation, hydroxylation, demethylation)
affects drug transfer across the placenta
 At term, the surface area of the placenta is at its maximum and nearly
all substances can reach the fetus
Drug Transfer
 Most drugs have a molecular weight below 1000 daltons (D)
 Drugs  1000 D cross the placenta ( 500 D cross easily)
 Main determinant of the drug concentration in the
embryo/fetus is the mother's blood concentration
 Other factors:-
lipid solubility & protein binding
degree of ionization at physiologic pH
placental blood flow & surface area available for transfer
The Processes That Govern The Passage Of A Drug Into
Milk Are Similar To The Placenta
 Maternal serumconcentration is the main determinant
 The milk pH is slightly acidic in comparison to serumpH;
so weak bases couldbecome trappedin milk (ion
trapping).
Fetal Age Affects The Type Of Drug Effect:
 Before the 20thday after fertilization :
 (all-or-nothing effect), Teratogenesis is unlikely during this
stage.
 During organogenesis (between 20 and 56 days after fertilization):
 Teratogenesis is most likely at this stage, spontaneous abortion,
gross anatomic defect (true teratogenic effect), or the drugs
may have no measurable effect.
 After organogenesis (in the2nd and 3rd trimesters):
 Teratogenesis is unlikely, but drugs may alter growth and
function of normally formed fetal organs and tissues
Timing Of The Development Of Major Body
Structures In The Embryo And Fetus
Type Of Effects
 Teratogenicity (e.g. thalidomide) - detected at, or shortly after,
birth .
 Long term latency (e.g. DES - increased risk of vaginal
adenocarcinoma after puberty, or abnormalities in testicular
function and semen production) .
 Predisposition to metabolic diseases (e.g. Barker hypothesis -
low birth weight associated with increased risk of diabetes,
hypertension, heart disease in adulthood).
 Impaired intellectual or social development(e.g. exposure to
phenobarbitone- alters programming of brain)
Teratogenesis
Teratogenesis
 It is defined as structural or functional dysgenesis of the fetal
organs.
 Typical manifestations include
congenital malformations with varying severity
intrauterine growth restriction
carcinogenesis
fetal demise
 In humans, the critical time for drug-induced congenital
malformations is in the first trimester
Malformations
 The overall incidence of
major congenital malformations is around 2-3%
minor malformations is 9%
25% are due to genetic or chromosomal abnormalities
10% due to environmental causes including drugs
65% of unknown aetiology
 The part played by drugs is probably small
Organogenesis
 The critical time for drug-induced congenital malformations is
usually the period of organogenesis
about 20 to 55 days after conception
about 34 to 69 days (5-10 weeks) after the first day of the LMP
 If a drug is given after this time it will not produce a major
anatomical defect, but more of a functional one
Pregnancy Risk Categories - FDA
 Category |A| Safety has been established using human studies, no
fetal risk.
 Category |B| Presumed safety based on animal studies, but no well-
controlled human studies.
 Category |C|Uncertain safety. Animal studies show an adverse
effect, no human studies.
 Category |D| Evidence of fetal risk, but benefits outweigh risks.
 Category |X| Highly unsafe. Risk outweighs any possible benefit.
Antibiotics
Category |B|
Penicillin | Cephalosporin | Macrolides | Nitrofurantoin |
Metronidazole | Vancomycin (oral)
Antibiotics… Cont.
 Penicillin one of the safest antibiotics that could be used in pregnancy
 Cephalosporin one of the safest antibiotics in pregnancy
 Macrolides; erythromycin& azithromycin can be used.
 Nitrofurantoin;Commonly used in pregnancy to treat UTI should not be
given to women in late pregnancy due to the potential risk of hemolytic
anemia in the newborn.
 Metronidazole; not recommended for lactation
 Vancomycin (oral); possible fetal ototoxic effect
Antibiotics… Cont.
Category |C|
Aminoglycoside [neomycin – tobramycin]| Quinolones |
Trimethoprim | Chloramphenicol
Quinolones [ciprofloxacin – levofloxacin]; There are safety
concerns of fluoroquinolone use during pregnancy and, as a
result, are contraindicated except for when no other safe
alternative antibiotic exists.
Trimethoprim; can affect folate metabolism, so; relatively
contraindicated during pregnancy, especially the 1st trimester.
Chloramphenicol; Gray Baby Syndrome
Antibiotics… Cont.
Category |D|
Tetracycline | Aminoglycosides [streptomycin –
gentamicin]
Tetracycline; use during tooth development can cause
permanent discoloration & enamel hypoplasia.
Aminoglycosides [streptomycin – gentamicin]; hearing
deficit & 8th cranial nerve damage
Antivirals
Acyclovir |B| recommended for treatment of Varicella during
pregnancy, especially during the 2nd and 3rd trimesters
Amantadine|C| CHD; tetralogy of Fallot / single ventricle with
pulmonary atresia
Anti-retroviral agents|B|
[Didanosine – Etravirine – Ritonavir – Enfuviritide – Maraviroc]
Anti-retroviral agents|C|
[Lamivudine – Delaviridine – Indinavir ]
Antifungals
Category |B|
Amphotericin b | remains the drug of choice for systemic
fungal infections in pregnancy despite its serious side
effects i.e. renal toxicity
Terbinafine; approved for the treatment of onychomycosis
Antifungals… Cont.
Category |C|
Ketoconazole; inhibits placental microsomal aromatase &
cytochrome P-450
Antifungals… Cont.
Category |C/D|
Fluconazole; depends on doses & duration of use
Antifungals… Cont.
Category |X|
 Griseofulvin; contraindicated during pregnancy &
pregnancy should be avoided for 1 month after
treatment
Antimalarial
 Chloroquine**; drug of choice for the prophylaxis and
treatment of sensitive malaria species during pregnancy.
Thalidomide***
Potent Teratogen |X|
was used against nausea and to alleviate
morning sickness in pregnant women.
 Meromelia
 CHD
 Eye abnormalities
 Facial Palsy
Phocomelia
Cytotoxic Drugs
 Methotrexate*** |X|; Potent teratogen that produces
major congenital anomalies.
 Cyclophosphamide*** – Chlorambucil ***|D|;
Teratogenic:
- growth restriction
- ear and facial abnormalities
- absence of digits
- hypoplastic limbs
Cytotoxic Drugs… Cont.
 Azathioprine** |D|; can cause birth defects
 Cyclosporine***|C|; does not appear to be a major
human teratogen; but could cause complications like:
- Preeclampsia
- Eclampsia
- Oligohydramnios
Anti-inflammatory Drugs
NSAIDs:
 Aspirin*** |D| in 3rd trimester
 Ibuprofen*** – diclofenac** - celecoxib* |D|; >30 weeks
could cause premature closure of DA
Anticonvulsants
Phenytoin** - Carbamazepine** |D|; Potent teratogen
Fetal HydantoinSyndrome || 5-10%
- IUGR
- Craniofacial anomalies
- Developmental delay
- Mental retardation
Anticonvulsants… Cont.
 Valproic Acid*|D|
- neural tube defects
- cognitive impairment
- dysmorphic features
- risk of autism
Diethylstilbestrol [Des]
Human teratogen |X|
- Vaginal adenosis
- Cervical erosions
- Transverse vaginal ridges
- Vaginal adenocarcinoma
Vitamin A Analogues
 Isotretinoin*** |X|; Potent teratogenic
- Severe birth defects
- Neuropsychological impairment
- Spontaneous abortion
- Premature birth
- Fetal death
- Internal abnormalities
ANTICOAGULANTS
 WARFARIN
• Adverse effects when given during the 1st trimester, fetal warfarin syndrome (e.G.
Nasal hypoplasia, epiphyses stippling, bilateral optic atrophy, various degrees of
intellectual disability)
• Adverse effects when given during the 2nd or 3rd trimester, optic atrophy, cataracts,
intellectual disability, microcephaly, microphthalmia, and fetal and maternal
hemorrhage.
• FDA Pregnancy category |X/D| for women with mechanical heart valves who are at
high risk for thromboembolism.
 HEPARIN
• Heparins are used for the management of venous thromboembolism in pregnancy
because they do not cross the placenta.
• FDA Pregnancy category: Low molecular weight heparin: |B|
Unfractionated heparin: |C|
Cardiovascular drugs
 ACE inhibitors, ARBs
 Contraindicated in pregnancy. FDA pregnancy category |C| for the 1st trimester of
pregnancy and |D| during the 2nd and 3rd trimesters.
 Prenatal exposure to an ACE inhibitor (e.g. enalapril) or to an angiotensin II receptor
antagonist (e.g. losartan) during the 2nd or 3rd trimester of pregnancy is associated
with an increased risk for fetal hypotension, renal failure, and oligohydramnios
leading to fetal growth restriction, joint contractures, pulmonary hypoplasia, &
stillbirth or neonatal death.
 β-Blockers
 FDA Pregnancy category |C|
 Can cause Fetal bradycardia, hypoglycemia, & possibly fetal growth restriction
 Amiodarone
 FDA pregnancy category |D|; should only be given during pregnancy when there are no
alternatives and benefit outweighs risk.
 Ca channel blockers
 When given during the 1st trimester, possibly phalangeal deformities
 When given during the 2nd or 3rd trimester, fetal growth restriction
 FDA Pregnancy Category |C|
 Methyldopa
 FDA Pregnancy Category |B|
 Thiazide diuretics
 Can cause neonatal hyponatremia, hypokalemia, & thrombocytopenia
 FDA Pregnancy Category |D|
 Statins
 FDA pregnancy category |X|
 statins should be avoided during pregnancy
– congenital anomalies have been reported.
Insulin & Hypoglycemic Drugs
 insulin is the treatment of choice for diabetes during pregnancy.
 Neonates born to mothers with diabetes who are taking oral
hypoglycaemics in pregnancy may have hypoglycaemia.
 Metformin is FDA pregnancy category |B|.
Progesterone
 Danazol, Synthetic progestin (but not the low doses used in oral
contraceptives), when given during the first 14 wks., masculinization of a
female fetus's genitals. FDA pregnancy category |X|
 progestin exposure is associated with an increased prevalence of
cardiovascular abnormalities.
 Combined Oral contraceptive pills, when taken during the early stages of
an unrecognized pregnancy, are believed to be teratogenic agents.
Antithyroid drugs
 Carbimazole - Propylthiouracil (PTU)
 Both drugs cross the placenta and may cause fetal hypothyroidism in high doses. PTU is
preferred for new cases as there is less transfer across the placenta.
Corticosteroids
 When used during the 1st trimester, possibly orofacial clefts
 FDA pregnancy category |B|
 Hydrocortisone and prednisolone are largely (90%) metabolized by placental
dehydrogenase, but fluorinated corticosteroids (e.g. betamethasone) and dexamethasone
are not, thus making them the drugs of choice when treating the fetus is the aim of therapy,
such as for fetal lung maturation.
GI drugs
 Omeprazole does not seem to be teratogenic, but less is known about
other PPIs during pregnancy.
 Ranitidine crosses the placenta. Although the manufacturer advises use should be
avoided during pregnancy, epidemiological study reveals no increased prevalence of adverse
fetal outcomes. Rodent teratogenicity studies are reassuring.
 Metoclopramide has been assigned to pregnancy category B by the FDA
Dermatologic agents
 Based on large population-based follow-up studies, topical corticosteroids are generally
considered safe for use at any stage of pregnancy.
Benzodiazepines
 FDA pregnancy category |D|
 If benzodiazepines (especially those with a long half-life) are taken in late pregnancy,
they can cause neonatal respiratory depression, poor temperature regulation, poor
feeding and hypotonicity.
 There is a risk of neonatal withdrawal symptoms and craniofacial anomalies.
 Avoid regular use and use only if there is a clear indication such as seizure control.
Lithium
 FDA pregnancy category |D|
 Neonatal lethargy, hypotonia, poor feeding, hypothyroidism, goiter, and nephrogenic
diabetes insipidus
 Increased risk of Ebstein’s anomaly when it is used in early pregnancy.
SSRI
 Fluoxetine (category |C|) is the SSRI with lowest known risk in pregnancy.
 Paroxetine is category |D|
 SSRIs should not be used during pregnancy unless the potential benefit
outweighs the risk.
 There is a small increased risk of congenital heart defects when SSRIs are taken
during early pregnancy.
 If SSRIs are used during the third trimester there is a risk of neonatal
withdrawal symptoms, and persistent pulmonary hypertension in the newborn
has been reported.
Opioids
 Codeine, Meperidine, Morphine
 FDA pregnancy category |C|
 In neonates of women addicted to opioids, withdrawal symptoms possibly occurring
6 h to 8 days after birth
 With high doses given in the hour before delivery, possibly neonatal CNS depression
and bradycardia
Tricyclic antidepressants
 Tricyclic antidepressants (amitriptyline, imipramine, & nortriptyline) have lower known
risks than other newer antidepressants.
 There is no convincing evidence that any
of the drugs commonly used to treat
respiratory disorders cause particular
problems during pregnancy.
 Pseudoephedrine: possible risk of
gastroschisis. FDA pregnancy category |C|
 Loratadine; Possible risk of hypospadias.
FDA pregnancy category |B|
Vaccines
 Killed virus, toxoid, or recombinant vaccines may
be given during pregnancy.
 Live attenuated vaccines (varicella, measles, mumps, polio, and
rubella) should be given 3 months before pregnancy or postpartum.
Live virus vaccines are contra-indicated in pregnancy secondary to the
potential risk of fetal infection.
Caffeine
 Whether consuming caffeine in large amounts can increase perinatal
risk is unclear. Consuming caffeine in small amounts(e.g. 1 cup of
coffee/day) appears to pose little or no risk to the fetus.
 Some data, which did not account for tobacco or alcohol use, suggest that consuming
large amounts increases risk of stillbirths, preterm deliveries, low birth weight, and
spontaneous abortions.
Aspartame (artificial sweetener)
 Use during pregnancy is often questioned.
 The most common metabolite of aspartame, phenylalanine, is concentrated in the
fetus by active placental transport; toxic levels may cause intellectual disability.
However, when ingestion is within the usual range, fetal phenylalanine levels are far
below toxic levels. Thus, moderate ingestion of aspartame (e.g. no more than 1 liter of
diet soda per day) during pregnancy appears to pose little risk of fetal toxicity.
Smoking
 Carbon monoxide and nicotine in cigarettes cause hypoxia and vasoconstriction,
increasing risk of spontaneous abortion, fetal growth restriction, abruptio
placentae, placenta previa, premature rupture of the membranes, preterm birth,
chorioamnionitis, and stillbirth.
 Neonates whose mothers smoke are also more likely to have anencephaly, congenital
heart defects, orofacial clefts, sudden
infant death syndrome, deficiencies
in physical growth and intelligence,
and behavioral problems.
 Smoking during pregnancy is linked
to childhood asthma.
Alcohol
 Increases risk of spontaneous abortion.
 Decreases birth weight by about 1 to 1.3 kg if regular drinking.
 Binge drinking in particular can cause fetal alcohol syndrome. This
syndrome may include fetal growth restriction, facial and
cardiovascular defects, neurologic dysfunction, Vision or hearing
problems, behavioral, and intellectual disabilities.
 It can cause neonatal death due to failure to thrive (FTT)

Más contenido relacionado

La actualidad más candente

Drugs used in pregnancy
Drugs used in pregnancyDrugs used in pregnancy
Drugs used in pregnancyethan1hunt
 
Drug therapy in pregnancy
Drug therapy in pregnancyDrug therapy in pregnancy
Drug therapy in pregnancyjaharlal baidya
 
Drugs in pregnancy and lactation
Drugs in pregnancy and lactation Drugs in pregnancy and lactation
Drugs in pregnancy and lactation Mini Sood
 
Drug use in pregnancy
Drug use in pregnancy  Drug use in pregnancy
Drug use in pregnancy Htet Wai Moe
 
Drugs used or avoided in pregnancy
Drugs used or avoided in pregnancyDrugs used or avoided in pregnancy
Drugs used or avoided in pregnancymostafa hosni
 
DRUGS IN PREGNANCY
 				DRUGS IN PREGNANCY 				DRUGS IN PREGNANCY
DRUGS IN PREGNANCYgolden4host
 
Prescribing during pregnancy
Prescribing during pregnancyPrescribing during pregnancy
Prescribing during pregnancyPravin Prasad
 
Drug therapy in pregnancy and lactation
Drug therapy in pregnancy and lactationDrug therapy in pregnancy and lactation
Drug therapy in pregnancy and lactationVishnupriya K
 
Drugs in Pregnancy - Jaber Manasia
Drugs in Pregnancy - Jaber ManasiaDrugs in Pregnancy - Jaber Manasia
Drugs in Pregnancy - Jaber ManasiaJaber Manasia
 
Drug therapy during_pregnancy (1)
Drug therapy during_pregnancy (1)Drug therapy during_pregnancy (1)
Drug therapy during_pregnancy (1)Amira Badr
 
Prescribing in pregnancy
Prescribing in pregnancyPrescribing in pregnancy
Prescribing in pregnancyYogesh Patel
 
Pharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyPharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyReem Alyahya
 
Drugs used in pregnancy and lactation
Drugs used in pregnancy and lactationDrugs used in pregnancy and lactation
Drugs used in pregnancy and lactationKoppala RVS Chaitanya
 

La actualidad más candente (20)

Drugs used in pregnancy
Drugs used in pregnancyDrugs used in pregnancy
Drugs used in pregnancy
 
Drug therapy in pregnancy
Drug therapy in pregnancyDrug therapy in pregnancy
Drug therapy in pregnancy
 
Drugs in pregnancy and lactation
Drugs in pregnancy and lactation Drugs in pregnancy and lactation
Drugs in pregnancy and lactation
 
Drug use in pregnancy
Drug use in pregnancy  Drug use in pregnancy
Drug use in pregnancy
 
Medication during pregnancy
Medication during pregnancyMedication during pregnancy
Medication during pregnancy
 
Drugs and pregnancy
Drugs and pregnancyDrugs and pregnancy
Drugs and pregnancy
 
Drugs & lactation
Drugs & lactationDrugs & lactation
Drugs & lactation
 
Drugs used or avoided in pregnancy
Drugs used or avoided in pregnancyDrugs used or avoided in pregnancy
Drugs used or avoided in pregnancy
 
DRUGS IN PREGNANCY
 				DRUGS IN PREGNANCY 				DRUGS IN PREGNANCY
DRUGS IN PREGNANCY
 
Drug Safety in Pregnancy and Lactation
Drug Safety in Pregnancy and LactationDrug Safety in Pregnancy and Lactation
Drug Safety in Pregnancy and Lactation
 
Prescribing during pregnancy
Prescribing during pregnancyPrescribing during pregnancy
Prescribing during pregnancy
 
Drug therapy in pregnancy and lactation
Drug therapy in pregnancy and lactationDrug therapy in pregnancy and lactation
Drug therapy in pregnancy and lactation
 
Teratogen Drugs
Teratogen DrugsTeratogen Drugs
Teratogen Drugs
 
Pregnancy and pharmacology
Pregnancy and pharmacologyPregnancy and pharmacology
Pregnancy and pharmacology
 
Drugs in pregnancy
Drugs in pregnancyDrugs in pregnancy
Drugs in pregnancy
 
Drugs in Pregnancy - Jaber Manasia
Drugs in Pregnancy - Jaber ManasiaDrugs in Pregnancy - Jaber Manasia
Drugs in Pregnancy - Jaber Manasia
 
Drug therapy during_pregnancy (1)
Drug therapy during_pregnancy (1)Drug therapy during_pregnancy (1)
Drug therapy during_pregnancy (1)
 
Prescribing in pregnancy
Prescribing in pregnancyPrescribing in pregnancy
Prescribing in pregnancy
 
Pharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyPharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancy
 
Drugs used in pregnancy and lactation
Drugs used in pregnancy and lactationDrugs used in pregnancy and lactation
Drugs used in pregnancy and lactation
 

Destacado

Pharmacotherapy in obstetrics
Pharmacotherapy in obstetricsPharmacotherapy in obstetrics
Pharmacotherapy in obstetricsberbets
 
COMMON Drugs used in obstetric emergencies
 COMMON Drugs used in obstetric emergencies COMMON Drugs used in obstetric emergencies
COMMON Drugs used in obstetric emergenciesGarden City College
 
Manag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicManag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicimelhakim
 
Pregnancy categories of drugs
Pregnancy categories of drugsPregnancy categories of drugs
Pregnancy categories of drugsJORGE DE AVILA
 
Medications during pregnancy
Medications during pregnancyMedications during pregnancy
Medications during pregnancyDr. Salman Iqbal
 
Oral contraceptives
Oral contraceptivesOral contraceptives
Oral contraceptivesvelspharmd
 
Contraception ppt
Contraception pptContraception ppt
Contraception pptaobyle
 
Family planning....ppt
Family planning....pptFamily planning....ppt
Family planning....pptMonika Sharma
 

Destacado (13)

Pharmacotherapy in obstetrics
Pharmacotherapy in obstetricsPharmacotherapy in obstetrics
Pharmacotherapy in obstetrics
 
COMMON Drugs used in obstetric emergencies
 COMMON Drugs used in obstetric emergencies COMMON Drugs used in obstetric emergencies
COMMON Drugs used in obstetric emergencies
 
Pharmacotherapeutics in obstetrics
Pharmacotherapeutics in obstetricsPharmacotherapeutics in obstetrics
Pharmacotherapeutics in obstetrics
 
Drug ppt lisa chadha
Drug ppt lisa chadhaDrug ppt lisa chadha
Drug ppt lisa chadha
 
Manag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicManag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinic
 
Pregnancy categories of drugs
Pregnancy categories of drugsPregnancy categories of drugs
Pregnancy categories of drugs
 
Medications during pregnancy
Medications during pregnancyMedications during pregnancy
Medications during pregnancy
 
Family planning
Family planningFamily planning
Family planning
 
Oral contraceptives
Oral contraceptivesOral contraceptives
Oral contraceptives
 
METHODS OF CONTRACEPTION
METHODS OF CONTRACEPTION METHODS OF CONTRACEPTION
METHODS OF CONTRACEPTION
 
Hormonal contraceptives satya ppt
Hormonal contraceptives satya pptHormonal contraceptives satya ppt
Hormonal contraceptives satya ppt
 
Contraception ppt
Contraception pptContraception ppt
Contraception ppt
 
Family planning....ppt
Family planning....pptFamily planning....ppt
Family planning....ppt
 

Similar a drugs in pregnancy

Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyabhishekbharti51
 
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyabhishekbharti51
 
Repro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfRepro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfSanjayaManiDixit
 
Drug safety (1)
Drug safety (1)Drug safety (1)
Drug safety (1)drmcbansal
 
7 drugs in pregnancy2010
7 drugs in pregnancy20107 drugs in pregnancy2010
7 drugs in pregnancy2010obsgyna
 
Drug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxDrug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxindiarto1
 
Antiprotozoal Agents Sia Salamat Et Al
Antiprotozoal Agents Sia Salamat Et AlAntiprotozoal Agents Sia Salamat Et Al
Antiprotozoal Agents Sia Salamat Et Alguest151c
 
drugseffectonthepregnancy-170219000730.pdf
drugseffectonthepregnancy-170219000730.pdfdrugseffectonthepregnancy-170219000730.pdf
drugseffectonthepregnancy-170219000730.pdfAbisha62
 
Drugs effect on the pregnancy
Drugs effect on the pregnancyDrugs effect on the pregnancy
Drugs effect on the pregnancywisam alsaedi
 
Oral surgery during pregnancy
Oral surgery during pregnancyOral surgery during pregnancy
Oral surgery during pregnancyAhmed Adawy
 
Maternal drug intake and breastfeeding
Maternal drug intake and breastfeedingMaternal drug intake and breastfeeding
Maternal drug intake and breastfeedingPriyanka Gohil
 
Teratogenicity and the drugs causing it
Teratogenicity and the drugs causing itTeratogenicity and the drugs causing it
Teratogenicity and the drugs causing itTheDReamer3
 
Issues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientsIssues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientssamthamby79
 
Teratology dr. hussein abass 2006
Teratology     dr. hussein abass    2006Teratology     dr. hussein abass    2006
Teratology dr. hussein abass 2006Hosin Abass
 

Similar a drugs in pregnancy (20)

Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancy
 
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancy
 
Repro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfRepro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdf
 
Drug safety (1)
Drug safety (1)Drug safety (1)
Drug safety (1)
 
7 drugs in pregnancy2010
7 drugs in pregnancy20107 drugs in pregnancy2010
7 drugs in pregnancy2010
 
Drug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxDrug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptx
 
Teratogens
TeratogensTeratogens
Teratogens
 
Antiprotozoal Agents Sia Salamat Et Al
Antiprotozoal Agents Sia Salamat Et AlAntiprotozoal Agents Sia Salamat Et Al
Antiprotozoal Agents Sia Salamat Et Al
 
drugseffectonthepregnancy-170219000730.pdf
drugseffectonthepregnancy-170219000730.pdfdrugseffectonthepregnancy-170219000730.pdf
drugseffectonthepregnancy-170219000730.pdf
 
Drugs effect on the pregnancy
Drugs effect on the pregnancyDrugs effect on the pregnancy
Drugs effect on the pregnancy
 
Teratology
TeratologyTeratology
Teratology
 
Oral surgery during pregnancy
Oral surgery during pregnancyOral surgery during pregnancy
Oral surgery during pregnancy
 
Maternal drug intake and breastfeeding
Maternal drug intake and breastfeedingMaternal drug intake and breastfeeding
Maternal drug intake and breastfeeding
 
Teratogenic antibiotics
Teratogenic antibioticsTeratogenic antibiotics
Teratogenic antibiotics
 
Teratogenicity and the drugs causing it
Teratogenicity and the drugs causing itTeratogenicity and the drugs causing it
Teratogenicity and the drugs causing it
 
Pregnancy.pptx
Pregnancy.pptxPregnancy.pptx
Pregnancy.pptx
 
8. Teratology.pptx
8. Teratology.pptx8. Teratology.pptx
8. Teratology.pptx
 
Issues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientsIssues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patients
 
seminar on maternal drugs
seminar on maternal  drugsseminar on maternal  drugs
seminar on maternal drugs
 
Teratology dr. hussein abass 2006
Teratology     dr. hussein abass    2006Teratology     dr. hussein abass    2006
Teratology dr. hussein abass 2006
 

Más de mt53y8

Systemic Lupus Erythematosus .pptx
Systemic Lupus Erythematosus  .pptxSystemic Lupus Erythematosus  .pptx
Systemic Lupus Erythematosus .pptxmt53y8
 
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphomaDiffuse large B-cell lymphoma
Diffuse large B-cell lymphomamt53y8
 
Megaloblastic anemias
Megaloblastic anemiasMegaloblastic anemias
Megaloblastic anemiasmt53y8
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertensionmt53y8
 
Clostridium difficile
Clostridium difficileClostridium difficile
Clostridium difficilemt53y8
 
Malabsorptive disorders final presentation
Malabsorptive disorders   final presentationMalabsorptive disorders   final presentation
Malabsorptive disorders final presentationmt53y8
 
Antibiotics vs appendectomy
Antibiotics vs appendectomyAntibiotics vs appendectomy
Antibiotics vs appendectomymt53y8
 
21. lower gi bleeding
21. lower gi bleeding21. lower gi bleeding
21. lower gi bleedingmt53y8
 
cervical cancer
 cervical cancer cervical cancer
cervical cancermt53y8
 
5 breast disorders
5  breast disorders5  breast disorders
5 breast disordersmt53y8
 
S ameer 2015 dysuria
S ameer 2015    dysuriaS ameer 2015    dysuria
S ameer 2015 dysuriamt53y8
 
rhinosinusitis
  rhinosinusitis  rhinosinusitis
rhinosinusitismt53y8
 
Sore throat and streptococcal pharyngitis
Sore throat and streptococcal pharyngitisSore throat and streptococcal pharyngitis
Sore throat and streptococcal pharyngitismt53y8
 
Essential hypertension lecture
Essential hypertension lectureEssential hypertension lecture
Essential hypertension lecturemt53y8
 

Más de mt53y8 (15)

Systemic Lupus Erythematosus .pptx
Systemic Lupus Erythematosus  .pptxSystemic Lupus Erythematosus  .pptx
Systemic Lupus Erythematosus .pptx
 
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphomaDiffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
 
Megaloblastic anemias
Megaloblastic anemiasMegaloblastic anemias
Megaloblastic anemias
 
ACLS
ACLSACLS
ACLS
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Clostridium difficile
Clostridium difficileClostridium difficile
Clostridium difficile
 
Malabsorptive disorders final presentation
Malabsorptive disorders   final presentationMalabsorptive disorders   final presentation
Malabsorptive disorders final presentation
 
Antibiotics vs appendectomy
Antibiotics vs appendectomyAntibiotics vs appendectomy
Antibiotics vs appendectomy
 
21. lower gi bleeding
21. lower gi bleeding21. lower gi bleeding
21. lower gi bleeding
 
cervical cancer
 cervical cancer cervical cancer
cervical cancer
 
5 breast disorders
5  breast disorders5  breast disorders
5 breast disorders
 
S ameer 2015 dysuria
S ameer 2015    dysuriaS ameer 2015    dysuria
S ameer 2015 dysuria
 
rhinosinusitis
  rhinosinusitis  rhinosinusitis
rhinosinusitis
 
Sore throat and streptococcal pharyngitis
Sore throat and streptococcal pharyngitisSore throat and streptococcal pharyngitis
Sore throat and streptococcal pharyngitis
 
Essential hypertension lecture
Essential hypertension lectureEssential hypertension lecture
Essential hypertension lecture
 

Último

Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxtadehabte
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSapna Thakur
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 

Último (20)

Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 

drugs in pregnancy

  • 1. Drugs in pregnancy  SAMEERSALEH SAWAED  2016
  • 2. Drug Epidemiology  More than 50% of pregnant women take prescribed or non- prescribed (OTC) drugs or use social drugs (such as tobacco and alcohol) or illicit drugs at some time during pregnancy.  In general, drugs should NOT be used during pregnancy unless absolutely necessary because many can harm the fetus.  About 2-3% of all birth defects result from drugs that are taken to treat a disorder or symptom.
  • 3. Drug Disposition In The Maternal-fetal Unit
  • 4. Maternal Pharmacokinetics  Changes in body fluid volume  Changes in CVS parameters  Changes in pulmonary function  Alterations in gastric activity  Changes in serum binding protein concentrations and occupancy  Alterations in kidney function
  • 5. Fetal Pharmacokinetics  Plasma binding proteins differ from maternal.  Drugs transferred across placenta undergo 1st pass through the fetal liver.  Liver expresses metabolizing enzymes, but capacity less than mother.  Fetal kidney immature.
  • 6. Placental Pharmacokinetics  Blood flow through the placenta (maternal side) increases during gestation  Transfer of flow-limited drugs affected by placental flow  Compounds that alter blood flow alter maternal drug disposition and placental transfer  Placental metabolism (dealkylation, hydroxylation, demethylation) affects drug transfer across the placenta  At term, the surface area of the placenta is at its maximum and nearly all substances can reach the fetus
  • 7. Drug Transfer  Most drugs have a molecular weight below 1000 daltons (D)  Drugs  1000 D cross the placenta ( 500 D cross easily)  Main determinant of the drug concentration in the embryo/fetus is the mother's blood concentration  Other factors:- lipid solubility & protein binding degree of ionization at physiologic pH placental blood flow & surface area available for transfer
  • 8. The Processes That Govern The Passage Of A Drug Into Milk Are Similar To The Placenta  Maternal serumconcentration is the main determinant  The milk pH is slightly acidic in comparison to serumpH; so weak bases couldbecome trappedin milk (ion trapping).
  • 9. Fetal Age Affects The Type Of Drug Effect:  Before the 20thday after fertilization :  (all-or-nothing effect), Teratogenesis is unlikely during this stage.  During organogenesis (between 20 and 56 days after fertilization):  Teratogenesis is most likely at this stage, spontaneous abortion, gross anatomic defect (true teratogenic effect), or the drugs may have no measurable effect.  After organogenesis (in the2nd and 3rd trimesters):  Teratogenesis is unlikely, but drugs may alter growth and function of normally formed fetal organs and tissues
  • 10. Timing Of The Development Of Major Body Structures In The Embryo And Fetus
  • 11. Type Of Effects  Teratogenicity (e.g. thalidomide) - detected at, or shortly after, birth .  Long term latency (e.g. DES - increased risk of vaginal adenocarcinoma after puberty, or abnormalities in testicular function and semen production) .  Predisposition to metabolic diseases (e.g. Barker hypothesis - low birth weight associated with increased risk of diabetes, hypertension, heart disease in adulthood).  Impaired intellectual or social development(e.g. exposure to phenobarbitone- alters programming of brain)
  • 13. Teratogenesis  It is defined as structural or functional dysgenesis of the fetal organs.  Typical manifestations include congenital malformations with varying severity intrauterine growth restriction carcinogenesis fetal demise  In humans, the critical time for drug-induced congenital malformations is in the first trimester
  • 14. Malformations  The overall incidence of major congenital malformations is around 2-3% minor malformations is 9% 25% are due to genetic or chromosomal abnormalities 10% due to environmental causes including drugs 65% of unknown aetiology  The part played by drugs is probably small
  • 15. Organogenesis  The critical time for drug-induced congenital malformations is usually the period of organogenesis about 20 to 55 days after conception about 34 to 69 days (5-10 weeks) after the first day of the LMP  If a drug is given after this time it will not produce a major anatomical defect, but more of a functional one
  • 16. Pregnancy Risk Categories - FDA  Category |A| Safety has been established using human studies, no fetal risk.  Category |B| Presumed safety based on animal studies, but no well- controlled human studies.  Category |C|Uncertain safety. Animal studies show an adverse effect, no human studies.  Category |D| Evidence of fetal risk, but benefits outweigh risks.  Category |X| Highly unsafe. Risk outweighs any possible benefit.
  • 17. Antibiotics Category |B| Penicillin | Cephalosporin | Macrolides | Nitrofurantoin | Metronidazole | Vancomycin (oral)
  • 18. Antibiotics… Cont.  Penicillin one of the safest antibiotics that could be used in pregnancy  Cephalosporin one of the safest antibiotics in pregnancy  Macrolides; erythromycin& azithromycin can be used.  Nitrofurantoin;Commonly used in pregnancy to treat UTI should not be given to women in late pregnancy due to the potential risk of hemolytic anemia in the newborn.  Metronidazole; not recommended for lactation  Vancomycin (oral); possible fetal ototoxic effect
  • 19. Antibiotics… Cont. Category |C| Aminoglycoside [neomycin – tobramycin]| Quinolones | Trimethoprim | Chloramphenicol Quinolones [ciprofloxacin – levofloxacin]; There are safety concerns of fluoroquinolone use during pregnancy and, as a result, are contraindicated except for when no other safe alternative antibiotic exists. Trimethoprim; can affect folate metabolism, so; relatively contraindicated during pregnancy, especially the 1st trimester. Chloramphenicol; Gray Baby Syndrome
  • 20. Antibiotics… Cont. Category |D| Tetracycline | Aminoglycosides [streptomycin – gentamicin] Tetracycline; use during tooth development can cause permanent discoloration & enamel hypoplasia. Aminoglycosides [streptomycin – gentamicin]; hearing deficit & 8th cranial nerve damage
  • 21. Antivirals Acyclovir |B| recommended for treatment of Varicella during pregnancy, especially during the 2nd and 3rd trimesters Amantadine|C| CHD; tetralogy of Fallot / single ventricle with pulmonary atresia Anti-retroviral agents|B| [Didanosine – Etravirine – Ritonavir – Enfuviritide – Maraviroc] Anti-retroviral agents|C| [Lamivudine – Delaviridine – Indinavir ]
  • 22. Antifungals Category |B| Amphotericin b | remains the drug of choice for systemic fungal infections in pregnancy despite its serious side effects i.e. renal toxicity Terbinafine; approved for the treatment of onychomycosis
  • 23. Antifungals… Cont. Category |C| Ketoconazole; inhibits placental microsomal aromatase & cytochrome P-450
  • 24. Antifungals… Cont. Category |C/D| Fluconazole; depends on doses & duration of use
  • 25. Antifungals… Cont. Category |X|  Griseofulvin; contraindicated during pregnancy & pregnancy should be avoided for 1 month after treatment
  • 26. Antimalarial  Chloroquine**; drug of choice for the prophylaxis and treatment of sensitive malaria species during pregnancy.
  • 27. Thalidomide*** Potent Teratogen |X| was used against nausea and to alleviate morning sickness in pregnant women.  Meromelia  CHD  Eye abnormalities  Facial Palsy Phocomelia
  • 28. Cytotoxic Drugs  Methotrexate*** |X|; Potent teratogen that produces major congenital anomalies.  Cyclophosphamide*** – Chlorambucil ***|D|; Teratogenic: - growth restriction - ear and facial abnormalities - absence of digits - hypoplastic limbs
  • 29. Cytotoxic Drugs… Cont.  Azathioprine** |D|; can cause birth defects  Cyclosporine***|C|; does not appear to be a major human teratogen; but could cause complications like: - Preeclampsia - Eclampsia - Oligohydramnios
  • 30. Anti-inflammatory Drugs NSAIDs:  Aspirin*** |D| in 3rd trimester  Ibuprofen*** – diclofenac** - celecoxib* |D|; >30 weeks could cause premature closure of DA
  • 31. Anticonvulsants Phenytoin** - Carbamazepine** |D|; Potent teratogen Fetal HydantoinSyndrome || 5-10% - IUGR - Craniofacial anomalies - Developmental delay - Mental retardation
  • 32. Anticonvulsants… Cont.  Valproic Acid*|D| - neural tube defects - cognitive impairment - dysmorphic features - risk of autism
  • 33. Diethylstilbestrol [Des] Human teratogen |X| - Vaginal adenosis - Cervical erosions - Transverse vaginal ridges - Vaginal adenocarcinoma
  • 34. Vitamin A Analogues  Isotretinoin*** |X|; Potent teratogenic - Severe birth defects - Neuropsychological impairment - Spontaneous abortion - Premature birth - Fetal death - Internal abnormalities
  • 35. ANTICOAGULANTS  WARFARIN • Adverse effects when given during the 1st trimester, fetal warfarin syndrome (e.G. Nasal hypoplasia, epiphyses stippling, bilateral optic atrophy, various degrees of intellectual disability) • Adverse effects when given during the 2nd or 3rd trimester, optic atrophy, cataracts, intellectual disability, microcephaly, microphthalmia, and fetal and maternal hemorrhage. • FDA Pregnancy category |X/D| for women with mechanical heart valves who are at high risk for thromboembolism.  HEPARIN • Heparins are used for the management of venous thromboembolism in pregnancy because they do not cross the placenta. • FDA Pregnancy category: Low molecular weight heparin: |B| Unfractionated heparin: |C|
  • 36. Cardiovascular drugs  ACE inhibitors, ARBs  Contraindicated in pregnancy. FDA pregnancy category |C| for the 1st trimester of pregnancy and |D| during the 2nd and 3rd trimesters.  Prenatal exposure to an ACE inhibitor (e.g. enalapril) or to an angiotensin II receptor antagonist (e.g. losartan) during the 2nd or 3rd trimester of pregnancy is associated with an increased risk for fetal hypotension, renal failure, and oligohydramnios leading to fetal growth restriction, joint contractures, pulmonary hypoplasia, & stillbirth or neonatal death.  β-Blockers  FDA Pregnancy category |C|  Can cause Fetal bradycardia, hypoglycemia, & possibly fetal growth restriction
  • 37.  Amiodarone  FDA pregnancy category |D|; should only be given during pregnancy when there are no alternatives and benefit outweighs risk.  Ca channel blockers  When given during the 1st trimester, possibly phalangeal deformities  When given during the 2nd or 3rd trimester, fetal growth restriction  FDA Pregnancy Category |C|  Methyldopa  FDA Pregnancy Category |B|
  • 38.  Thiazide diuretics  Can cause neonatal hyponatremia, hypokalemia, & thrombocytopenia  FDA Pregnancy Category |D|  Statins  FDA pregnancy category |X|  statins should be avoided during pregnancy – congenital anomalies have been reported.
  • 39. Insulin & Hypoglycemic Drugs  insulin is the treatment of choice for diabetes during pregnancy.  Neonates born to mothers with diabetes who are taking oral hypoglycaemics in pregnancy may have hypoglycaemia.  Metformin is FDA pregnancy category |B|.
  • 40. Progesterone  Danazol, Synthetic progestin (but not the low doses used in oral contraceptives), when given during the first 14 wks., masculinization of a female fetus's genitals. FDA pregnancy category |X|  progestin exposure is associated with an increased prevalence of cardiovascular abnormalities.  Combined Oral contraceptive pills, when taken during the early stages of an unrecognized pregnancy, are believed to be teratogenic agents.
  • 41. Antithyroid drugs  Carbimazole - Propylthiouracil (PTU)  Both drugs cross the placenta and may cause fetal hypothyroidism in high doses. PTU is preferred for new cases as there is less transfer across the placenta. Corticosteroids  When used during the 1st trimester, possibly orofacial clefts  FDA pregnancy category |B|  Hydrocortisone and prednisolone are largely (90%) metabolized by placental dehydrogenase, but fluorinated corticosteroids (e.g. betamethasone) and dexamethasone are not, thus making them the drugs of choice when treating the fetus is the aim of therapy, such as for fetal lung maturation.
  • 42. GI drugs  Omeprazole does not seem to be teratogenic, but less is known about other PPIs during pregnancy.  Ranitidine crosses the placenta. Although the manufacturer advises use should be avoided during pregnancy, epidemiological study reveals no increased prevalence of adverse fetal outcomes. Rodent teratogenicity studies are reassuring.  Metoclopramide has been assigned to pregnancy category B by the FDA Dermatologic agents  Based on large population-based follow-up studies, topical corticosteroids are generally considered safe for use at any stage of pregnancy.
  • 43. Benzodiazepines  FDA pregnancy category |D|  If benzodiazepines (especially those with a long half-life) are taken in late pregnancy, they can cause neonatal respiratory depression, poor temperature regulation, poor feeding and hypotonicity.  There is a risk of neonatal withdrawal symptoms and craniofacial anomalies.  Avoid regular use and use only if there is a clear indication such as seizure control. Lithium  FDA pregnancy category |D|  Neonatal lethargy, hypotonia, poor feeding, hypothyroidism, goiter, and nephrogenic diabetes insipidus  Increased risk of Ebstein’s anomaly when it is used in early pregnancy.
  • 44. SSRI  Fluoxetine (category |C|) is the SSRI with lowest known risk in pregnancy.  Paroxetine is category |D|  SSRIs should not be used during pregnancy unless the potential benefit outweighs the risk.  There is a small increased risk of congenital heart defects when SSRIs are taken during early pregnancy.  If SSRIs are used during the third trimester there is a risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn has been reported.
  • 45. Opioids  Codeine, Meperidine, Morphine  FDA pregnancy category |C|  In neonates of women addicted to opioids, withdrawal symptoms possibly occurring 6 h to 8 days after birth  With high doses given in the hour before delivery, possibly neonatal CNS depression and bradycardia Tricyclic antidepressants  Tricyclic antidepressants (amitriptyline, imipramine, & nortriptyline) have lower known risks than other newer antidepressants.
  • 46.  There is no convincing evidence that any of the drugs commonly used to treat respiratory disorders cause particular problems during pregnancy.  Pseudoephedrine: possible risk of gastroschisis. FDA pregnancy category |C|  Loratadine; Possible risk of hypospadias. FDA pregnancy category |B|
  • 47. Vaccines  Killed virus, toxoid, or recombinant vaccines may be given during pregnancy.  Live attenuated vaccines (varicella, measles, mumps, polio, and rubella) should be given 3 months before pregnancy or postpartum. Live virus vaccines are contra-indicated in pregnancy secondary to the potential risk of fetal infection.
  • 48. Caffeine  Whether consuming caffeine in large amounts can increase perinatal risk is unclear. Consuming caffeine in small amounts(e.g. 1 cup of coffee/day) appears to pose little or no risk to the fetus.  Some data, which did not account for tobacco or alcohol use, suggest that consuming large amounts increases risk of stillbirths, preterm deliveries, low birth weight, and spontaneous abortions. Aspartame (artificial sweetener)  Use during pregnancy is often questioned.  The most common metabolite of aspartame, phenylalanine, is concentrated in the fetus by active placental transport; toxic levels may cause intellectual disability. However, when ingestion is within the usual range, fetal phenylalanine levels are far below toxic levels. Thus, moderate ingestion of aspartame (e.g. no more than 1 liter of diet soda per day) during pregnancy appears to pose little risk of fetal toxicity.
  • 49. Smoking  Carbon monoxide and nicotine in cigarettes cause hypoxia and vasoconstriction, increasing risk of spontaneous abortion, fetal growth restriction, abruptio placentae, placenta previa, premature rupture of the membranes, preterm birth, chorioamnionitis, and stillbirth.  Neonates whose mothers smoke are also more likely to have anencephaly, congenital heart defects, orofacial clefts, sudden infant death syndrome, deficiencies in physical growth and intelligence, and behavioral problems.  Smoking during pregnancy is linked to childhood asthma.
  • 50. Alcohol  Increases risk of spontaneous abortion.  Decreases birth weight by about 1 to 1.3 kg if regular drinking.  Binge drinking in particular can cause fetal alcohol syndrome. This syndrome may include fetal growth restriction, facial and cardiovascular defects, neurologic dysfunction, Vision or hearing problems, behavioral, and intellectual disabilities.  It can cause neonatal death due to failure to thrive (FTT)